Acute generalized exanthematous pustulosis following treatment with favipiravir in a patient with COVID‐19 without hydroxychloroquine use: Report of the first case

Favipiravir is an antiviral agent used in the treatment of COVID-19 infection, and related cutaneous adverse events are rare 1 . Acute generalized exanthematous pustulosis (AGEP) has been reported in COVID-19 patients, mostly associated with hydroxychloroquine (HCQ). There are few AGEP cases in COVID-19 patients reported due to β-lactam antibiotics 2,3 in the literature. Herein, we report the first case of favipiravir-induced AGEP with histologic findings.